The NM_000152.5:c.2174G>C variant in GAA is a missense variant that results in the substitution of arginine by proline at amino acid 725 (p.Arg725Pro). This variant has been reported in one patient, in a study from China, diagnosed with infantile onset Pompe disease with <1% GAA activity in fibroblasts (PMID: 18458862) (PP4_Moderate). This patient was compound heterozygous for the variant and another variant in GAA that has been classified as pathogenic by the ClinGen LD VCEP, c.1935C>A (p.Asp645Glu) (ClinVar Variation ID: 4029) (PMID: 18458862); the phase is unknown. 0.5 points (PM3_Supporting). The variant is absent in gnomAD v4.1.0. (PM2_Supporting). The computational predictor REVEL gives a score of 0.973 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). Another missense change at the same amino acid position, c.2173C>T (p.Arg725Trp) (ClinVar Variation ID: 4024), has been classified as pathogenic by the LD VCEP (PM5). In addition, c.2174G>A (p.Arg725Gln) (ClinVar Variation ID: 555727) has been identified in an individuals with a positive newborn screen for Pompe disease and is classified as a VUS by the LD VCEP. In summary, this variant meets the criteria to be classified as likely pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0.0.): PM5, PP4_Moderate, PP3, PM2_Supporting, PM3_Supporting (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel, August 31, 2025)